Live tape
Top 8, mentions 7d29,868NVDA14,487 mentions▲ +0.04ANT4,135 mentions▲ +0.06GOOGL2,919 mentions▲ +0.04SPY2,244 mentions▲ +0.05QQQ1,799 mentions▲ +0.04SPCX1,742 mentions▲ +0.08AMD1,362 mentions▲ +0.06AAPL1,180 mentions▲ +0.04

Equity · Healthcare

XENE

NASDAQ

Xenon Pharmaceuticals (XENE)

33.50 USD −2.46% vs prior close Oct 16, 2026
Xenon Pharmaceuticals Inc. price graph
21 sessions
42.5 32.5 18 Sep 16 Oct

The line runs 40 USD on 18 September through 33.50 USD on 16 October, on a scale from 32.5 to 42.5. Days the market did not trade hold the previous close, flat.

Market cap
3.3B USD
Revenue, year to Dec 2025
7.5M USD
EPS, diluted, year to Dec 2025
−4.36 USD
52-week range
33.50 USD – 70.97 USD
Avg volume
286.2K

as of Oct 16, 2026

Have Xenon Pharmaceuticals (XENE) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Xenon Pharmaceuticals insiders reported 1 open-market sale and 2 purchases (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 30 Sep 2026

2buys
1sells
$1.26Mnet bought
2other filings
Have Xenon Pharmaceuticals (XENE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Sep 2026Kelly Thomas PatrickChief Financial OfficerBuy15,000560K USD
30 Sep 2026MORTIMER IANPRESIDENT & CEOBuy30,0001.1M USD
28 Aug 2026KENNEY CHRISTOPHER JOHNChief Medical OfficerSell7,068426K USD
Bought2 open-market purchases45,000$1.68M
Sold1 open-market sale7,068$426K
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Xenon Pharmaceuticals (XENE) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
15 Oct 2026Kelly Thomas PatrickChief Financial OfficerOption exercise7,500
01 Sep 2026Svoronos DawnDirectorOption exercise5,14442K USD

Which funds hold Xenon Pharmaceuticals (XENE)?

10 of the 45 institutional funds we track reported a Xenon Pharmaceuticals position for the quarter ended 30 Sep 2026 — a combined 171.1M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Xenon Pharmaceuticals (XENE)?
FundPositionSharesValueShares q/q
Two Sigma InvestmentsHeld (±25%)1,443,05453.7M USD−12.2%
Point72 Asset ManagementAdded1,190,20144.3M USD+812.9%
Marshall WaceAdded897,50933.4M USD+30.2%
Baker Bros. AdvisorsHeld (±25%)370,20813.8M USD
Citadel AdvisorsTrimmed322,49812.0M USD−77.0%
Renaissance TechnologiesAdded277,20010.3M USD+48.1%
Man GroupTrimmed43,2971.6M USD−86.1%
D. E. Shaw & Co.Trimmed30,2431.1M USD−86.5%
Tudor Investment CorpTrimmed16,483613K USD−97.0%
AQR Capital ManagementHeld (±25%)8,713324K USD+20.0%

What has been filed or recorded for Xenon Pharmaceuticals (XENE)?

The filings we hold for Xenon Pharmaceuticals, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Xenon Pharmaceuticals (XENE)?
And
26 Oct 2026Fails to deliverShares failed to deliver3,450 shares122K USD notional · 0.004% of shares out
20 Oct 2026Fails to deliverShares failed to deliver340 shares12K USD notional · <0.001% of shares out
08 Oct 2026Fails to deliverShares failed to deliver44,074 shares1.6M USD notional · 0.045% of shares out
07 Oct 2026Fails to deliverShares failed to deliver44,640 shares1.6M USD notional · 0.045% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.11 USD
30 Sep 2026FinancialsTotal assets1.2B USDat period end
30 Sep 2026FinancialsTotal equity1.1B USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.11 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.17 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −4.36 USD
31 Dec 2025FinancialsRevenue7.5M USDfiscal year
31 Dec 2025FinancialsNet income−345.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−4.36 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.15 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −1.07 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.83 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −3.01 USD

What do people ask about Xenon Pharmaceuticals (XENE)?

From live data
What did Xenon Pharmaceuticals shares close at?33.50

Xenon Pharmaceuticals closed at 33.50 USD on 16 Oct 2026, down 2.46% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Xenon Pharmaceuticals’ market cap?3.3B

Xenon Pharmaceuticals is worth 3.3B USD by market value as of 16 Oct 2026, which is the share price times the shares on issue from its SEC filings.

What is Xenon Pharmaceuticals’ revenue?7.5M

Xenon Pharmaceuticals reported revenue of 7.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Xenon Pharmaceuticals insiders bought or sold shares recently?1 sale

In the 90 days to 22 Nov 2026, Xenon Pharmaceuticals insiders reported 1 open-market sale and 2 purchases (SEC Form 4). A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Xenon Pharmaceuticals?10 of 45

10 of the 45 funds we track reported a Xenon Pharmaceuticals position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Point72 Asset Management and Marshall Wace. See Funds

When did Xenon Pharmaceuticals last report earnings?−1.11

Xenon Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.11 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words